Dr. Megan S. Devine, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Emory University School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 322
Licensed in Texas since 2007, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Emory University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
TX license M7948 (first issued 2007; active) -
Critical Care Medicine (Internal Medicine) Physician
TX license M7948 (first issued 2007; active) -
Internal Medicine Physician
TX license M7948 (first issued 2007; active) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Christus Mother Frances Hospital Tyler, TX
- Christus Good Shepherd Medical Center Longview, TX
- Ut Health East Texas Tyler Regional Hospital Tyler, TX
- University of Texas Health Science Center at Tyler Tyler, TX
Medical groups
- University of Texas Health Science Center at Tyler-Facilty-Physician (122 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 322
- Services billed
- 1,337
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Test to measure expiratory airflow and volume | 156 | 132 |
| Established patient office or other outpatient visit, 20-29 minutes | 136 | 106 |
| Test to examine how well the lungs exchange gases | 126 | 111 |
| Test to determine lung volumes using sensors | 97 | 92 |
| Established patient office or other outpatient visit, 30-39 minutes | 46 | 37 |
| Test for exercise-induced lung stress | 32 | 32 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 21 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Tyler, TX | 214 |
| Azithromycin Other prescribers in Tyler, TX | 88 |
| Prednisone Other prescribers in Tyler, TX | 82 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Tyler, TX | 81 |
| Montelukast Sodium Other prescribers in Tyler, TX | 62 |
| Opsumit (macitentan) | 58 |
| Mycophenolate Mofetil Other prescribers in Tyler, TX | 54 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Tyler, TX | 52 |
| Trikafta (elexacaftor/tezacaftor/ivacaft) | 51 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Tyler, TX | 44 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 86 payments worth $2,032 in total to this clinician.
| GlaxoSmithKline, LLC. | $397 |
|---|---|
| Boston Scientific Corporation | $360 |
| Genzyme Corporation | $191 |
| Actelion Pharmaceuticals US, Inc. | $179 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $149 |
| Insmed, Inc. | $147 |
| AstraZeneca Pharmaceuticals LP | $92.45 |
| Regeneron Healthcare Solutions, Inc. | $75.78 |
| Food and Beverage | $1,932 |
|---|---|
| Education | $99.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. Sep 29, 2025 | Education OPSUMIT; UPTRAVI · Cardiology · in-kind | $99.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 7 companies. The companies reported $194,338 in research payments for these studies, mostly to the institutions running them.
- A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
Sanofi US Services Inc. · Completed · NCT06280391 - ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
Mannkind Corporation · Terminated · NCT06418711 - Verona
Verona Pharma, Inc. - Roche Cancer Screening Collection Study
Genentech, Inc. - A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inh…
AstraZeneca Pharmaceuticals LP - A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM)
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIR…
Boehringer Ingelheim International GmbH - A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM)
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.